fascaplysine has been researched along with Liver Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, G; Jia, W; Li, J; Liu, J; Liu, L; Yang, H; Zhao, L; Zhao, X | 1 |
1 other study(ies) available for fascaplysine and Liver Neoplasms
| Article | Year |
|---|---|
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p18; E2F Transcription Factors; Female; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glucose; Humans; Immunohistochemistry; Indoles; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Microscopy, Fluorescence; Middle Aged; Mutation; Phosphorylation; Protein-Arginine N-Methyltransferases; Retinoblastoma Binding Proteins; RNA Interference; RNA, Small Interfering; Ubiquitin-Protein Ligases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |